anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to the technical field of medical materials. Disclosed are an acid-induced in-situ generated luminescent cation radical probe, and a preparation therefor and a use thereof. The luminescent cation radical probe is obtained by oxidizing a compound represented by formula I under an acidic condition, and the structure of the luminescent cation radical probe is represented by formula II. Also disclosed is a preparation method for the luminescent cation radical probe. The cation radical probe of the present invention is generated by means of an in-situ reaction in an acidic environment, does not require separation, has the advantages of red to near-infrared luminescence, high generation efficiency and good stability, and can be used for fluorescence imaging. According to the cation radical probe of the present invention, in-situ imaging and gastrointestinal imaging in the acidic environment in the stomach can be achieved. The probe of the present invention is also used for preparing a probe for monitoring a food digestion process in the stomach or preparing a reagent for monitoring a treatment process of an anti-gastric acid drug for neutralizing gastric acid.
Horiuchi, Masahiro, Satomi Mitsui, and Tadashi Uno. Influence of smoking and alcohol habits on symptoms of acute mountain sickness on Mount Fuji: a questionnaire survey-based pilot study. High Alt Med Biol 00:000-000, 2024. Background: Acute cigarette smoking or alcohol intake would cause opposing vasculature effects that may influence acute mountain sickness (AMS). The present study aimed to investigate the effects of smoking and alcohol consumption behaviors, and acute smoking and consuming alcohol during ascent on AMS on Mount Fuji. Methods: This questionnaire survey study included 887 participants who climbed Mount Fuji and obtained information regarding sex, age, and smoking and alcohol habits, including behavior during ascent. Results: AMS prevalence was 45% for all participants. A univariate analysis revealed that younger participants (20-29 years) were associated with increased AMS prevalence (effect size [ES] = 0.102, p = 0.057) and severity (ES = 0.18, p = 0.01). A prediction model using multiple logistic regression indicated that several factors influenced AMS risk: younger age (p = 0.001), daily smoking habits (p = 0.021), no smoking (p = 0.033), or alcohol consumption during ascent (p = 0.096). Alcohol consumption during ascent had no effect on the increased AMS risk in younger participants (20-29 years), while alcohol consumption during ascent increased AMS risk for middle-age participants (50-59 years). Conclusion: Younger individuals are more likely to experience AMS. Smoking habits are associated with an increased AMS risk. It may be recommended that middle-aged climbers should ascend without consuming alcohol.
A 2-year dermal mouse carcinogenicity study was initiated with topical administration of 0.005%, 0.025% and 0.05% Tretinoin Gel. Although no drug-related tumors were observed in surviving animals, the irritating nature of the drug product precluded daily dosing, confounding data interpretation and reducing the biological significance of these results. 

Studies in hairless albino mice with a different formulation suggest that concurrent exposure to tretinoin may enhance the tumorigenic potential of carcinogenic doses of UVB and UVA light from a solar simulator. This effect was confirmed in a later study in pigmented mice, and dark pigmentation did not overcome the enhancement of photocarcinogenesis by 0.05% tretinoin. Although the significance of these studies to humans is not clear, patients should minimize exposure to sunlight or artificial ultraviolet irradiation sources.

The genotoxic potential of tretinoin was evaluated in an in vitro bacterial reversion test, an in vitro chromosomal aberration assay in human lymphocytes and an in vivo rat micronucleus assay. All tests were negative.

In dermal fertility studies of another tretinoin formulation in rats, slight (not statistically significant) decreases in sperm count and motility were seen at 0.5 mg/kg/day (3 mg/m2, approximately 4 times the clinical dose based on body surface area comparison), and slight (not statistically significant) increases in the number and percent of nonviable embryos in females treated with 0.25 mg/kg/day and above (1.5 mg/m2, approximately 2 times the clinical dose based on body surface area comparison) were observed.
The present invention discloses a polypeptide in a sodium pump alpha-subunit film outer region, and applications of the polypeptide to preparing medicine for regulating the activity of a sodium pump. The polypeptide in the sodium pump alpha-subunit film outer region is a kind of polypeptide containing amino acid sequences of the sodium pump alpha-subunit film outer region, and belongs to the applications of polypeptide or proteins. The polypeptide in the sodium pump alpha-subunit film outer region can influence the biological activity of the sodium pump of cell membranes, and has the potential for treating cardiovascular diseases. Moreover, the functions of the polypeptide for blocking or antagonizing the restriction of sodium pumps by Ouabain are tested in in-vitro experiments. Animal pharmacological experiments indicate that the polypeptide can reduce the blood pressure of animal models with high blood pressure, and therefore, the present invention can be used for treating cardiovascular diseases, and is particularly used for treating high blood pressure. Meanwhile, the present invention has the characteristics of conspicuous therapeutic effect, small side effect, etc.
The present invention provides a system and method for patient clinical data management. The system and method provide automated data gathering, processing and reporting. Test orders are generated using a patient clinical data management application and are transmitted to laboratory equipment. Test results are obtained by the patient clinical data management application directly from the laboratory equipment. Processing may be performed in conjunction with demographic and related data. Reporting is conducted in accordance with reporting requirements imposed from governmental or other regulatory bodies. Select information from the records may be provided to endpoint devices such as mobile telephones, websites, pagers or personal digital assistants for up to the minute reporting.
Polyvinyl alcohol with a degree of polymerization of 600 to 800 is partially esterified with phthalic anhydride to produce a product with a phthalyl content of 60-70% by weight and an acetyl content of 1,6 to 6,0% by weight which, being substantially insoluble in the stomach juices but soluble in the intestinal fluids is used as an enteric coating for solid medicinal oral dosage units. Esterification is performed by refluxing in an inert solvent, e.g. pyridine. picoline or methyl ethyl ketone. The reaction mixture is forced into aqueous mineral acid to precipitate the product which is usually applied as a coating from a solution e.g. 95% ethanol.ALSO:A solid medicinal oral dosage unit consists of a core containing at least one medicinal agent coated with an enteric film of polyvinyl alcohol having a degree of polymerization of 600 to 800 partially esterified with phthalic anhydide.  The esteric coating has a phthalyl content of 60-70% by weight, an acetyl content of 1,6 to 6,0% by weight.  It is applied from a solution, e.g. in 95% ethanol, the solution being applied in several increments to build up a layer of desired thickness. Solvent is removed by a stream of warm air and the units are dusted, e.g. with talc between layers while the coating is sticky to prevent their sticking together.  In example I, tablets containing brewers yeast concentrate, thiamine hydrochloride, riboflavin, niaciamide, hyridoxine hydrochloride, vitam B12, vitamin C and vitamin D are coated with a film of polyvinyl alcohol acetate phtlalate (phthalyl content 65%, acetyl content 4,8%) applied as a 30% w/v solution in 90% denatured alcohol. Example II is similar using tablets which contain ferrous sulphate, edible bone flour, vitamin A acetate, vitam D, vitamin B1, riboflanin, niacinamide, vitamin C and roduim iodide.  In both examples a standard sugar coating was applied over the entire layer.
The invention discloses a new technology for producing frozen mixed semen for controlling the gender of milk cow. Goat semen is used as foundation (2,000,000 to 3,000,000 pieces/0.25 ml) and is added with X/Y separation semen (500,000 to 1,000,000 pieces/0.25 ml) to produce the frozen semen for controlling the gender X/Y of the milk cow. The main content of the technology comprises the separation of milk cow X/Y sperms, the preparation of the basic goat semen (which can be substituted by the semen of pig, horse or deer with the equal number) and the production of the frozen semen for controlling the gender of the milk cow through the procedures of mixing and freezing two kinds of the semen according to requirements. The new technology can improve the production efficiency of the frozen semen for controlling the gender of the milk cow by 2 to 4 times and reduce the production cost by 50 to 70 percent simultaneously. The new technology improves the activity and the acrosome intact rate of sperms after the sperms are unfrozen, prolongs the time for having the insemination capacity after the frozen sperms are unfrozen so that the average pregnancy rate in a sexual period reaches over 50 percent; and the accuracy rate of gender control reaches over 90 percent. The new technology is also suitable for producing the frozen mixed semen for controlling the gender of beef cattle.
PROBLEM TO BE SOLVED: To obtain the subject new compound having specific physico-chemical properties, excellent inhibitory action on DNA synthase and inhibitory action on telomerase, useful as an antitumor agent. SOLUTION: This compound PF1195 is shown by the formula. The compound of the formula is obtained by culturing a fungus belonging to the genus Talaromyces, capable of producing the compound PF1195, and collecting the compound PF1195 from the culture product. Hydrochloride, hydrobromide, or the like, may be cited as the salt of the compound of the formula. PF1195 strain belonging to the genus Talaromyces separated from soil may be used as a fungus capable of producing the compound PF1195. Glucose, sucrose, thick melt syrup, soybean powder, wheat malt, or the like, are used as a nutrient source. A culture under aerobic conditions, especially a stationary culture, is preferable as the culture method. A proper culture temperature is 25-30 deg.C and the accumulation reaches the maximum is 2-14 days.  The purification is carried out by extraction with an organic solvent, followed by absorption and desorption method using an adsorbent.
Lateral Window Technique Augmentation for Maxillary Sinus without the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of membrane. Placement of Purus® Cancellous Allograft, stabilized by Biomend ™ Collagen membrane. Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
Tinnitus is a disturbing condition defined as the occurrence of acoustic hallucinations with no actual sound. Although the mechanisms underlying tinnitus have been explored extensively, the pathophysiology of the disease is not completely understood. Moreover, genes and potential treatment targets related to auditory hallucinations remain unknown. In this study, we examined transcriptional-profile changes in the medial geniculate body after noise-induced tinnitus in rats by performing RNA sequencing and validated differentially expressed genes via quantitative polymerase chain reaction analysis. The rat model of tinnitus was established by analyzing startle behavior based on gap-pre-pulse inhibition of acoustic startles. We identified 87 differently expressed genes, of which 40 were upregulated and 47 were downregulated. Pathway-enrichment analysis revealed that the differentially enriched genes in the tinnitus group were associated with pathway terms, such as coronavirus disease COVID-19, neuroactive ligand-receptor interaction. Protein-protein-interaction networks were established, and two hub genes (Rpl7a and AC136661.1) were identified among the selected genes. Further studies focusing on targeting and modulating these genes are required for developing potential treatments for noise-induced tinnitus in patients.
Until December 2014, intravenous thrombolysis was the only reperfusion therapy proven to be effective within 4 hours of a cerebral infarction and several studies showed a clear functional benefit of thrombectomy in combination with thrombolysis in the first six hours of proximal arterial occlusion. Cerebral haemorrhages following reperfusion treatments involve not only rupture of the blood-brain barrier, but also direct damage to vessels related to the equipment used and secondary toxicity to thrombolytics. The rupture of the blood-brain barrier which results from ischemia / reperfusion is responsible for stagnation of the contrast product on the exams performed after thrombectomy, but it is difficult to distinguish hyperdensities related to the stagnation of contrast product and Hemorrhage on a conventional scanner. Several techniques are available to evaluate the hyperdensities post endovascular cerebral reperfusion including: the dual energy ct, the flat panel CT performed in the angiography room and the conventional scanner. The Cone beam CT is a relevant exam because it is performed in the angiography room and does not require transporting the patient who can be agitated or intubated until the scanner. The reference imaging is the double energy scanner performed at the thrombectomy outlet. Some studies have shown an excellent negative predictive value of the flat panel CT to eliminate haemorrhage in post-thrombectomy but no study directly compared the results of the flat panel with the CT performed in immediate post-thrombectomy and even less with the double energy scanner, it is therefore difficult to assert the sensitivity and exact specificity of this exam to detect and distinguish haemorrhage from contrast stagnation. The investigators propose a direct comparison of the cone beam CT with the dual energy CT performed at the exit of thrombectomy.

Method: consecutive patients presenting acute ischemic stroke candidates to thrombectomy will be enrolled in one hospital center. A cone beam Ct will be performed at the end of the procedure as well as a dual energy CT and finally a CT 24 h after the thrombectomy. Predictive factors of hemorrhage transformation such blood barrier disruption will be studied secondarily.
The invention discloses an electronic case privacy protection method based on a blockchain, and relates to the technical field of medical blockchains. The method comprises the following steps: system initialization, attribute mechanism initialization and data owner registration; encrypting data; generating a secret key; and decrypting the encrypted data by using the key to obtain the electronic case data. The method introduces a blockchain technology, and realizes tamper resistance of medical record plaintext information, transparent and traceable authorization process of the attribute mechanism by utilizing the advantages of the blockchain. The decryption key is generated in two steps, so that the decryption overhead pressure of a data user is reduced. And (3) realizing the revocation of the access rights of the data user by utilizing a multi-step generation process of the secret key. The application is compared with other existing schemes, and the comparison analysis is carried out from the two aspects of calculated amount and storage amount, so that the superiority of the method is verified.
PURPOSE:To obtain a refreshing drink agent for quenching thirst having high safeness, by containing C29-sterol. CONSTITUTION:A refreshing drink agent for quenching thirst containing C29- sterol expressed by formulas I-IV as an ingredient. The refreshing drink agent for quenching thirst containing such C29-sterol as an ingredient is e.g. obtained as follows: Japanese pear fruit, soybean seed or garden pea seed is used as a starting substance. Fruit juice or squeeze juice obtained from the starting substance is concentrated to about 1/10-1/3 and the concentrate is extracted with an extracting liquid consisting of mixed system of low aliphatic alcohol and low boiling ester to afford low boiling extract soluble content. The extract in this stage can be also used as an ingredient of the above-mentioned refreshing drink agent. After extraction, the solvent is distilled under reduced pressure to provide the aimed refreshing drink agent. The refreshing drink agent for quenching thirst is blended with other food, e.g. refreshing drink water or refreshing cake to provide the refreshing drink agent for quenching thirst. The blend is carried out so as to be capable of taking the agent ingredient at an amount of 100mg/adult at a time.
Renal fibrosis plays a key role in the pathogenesis of chronic kidney disease (CKD), in which the persistent high expression of transforming growth factor β1 (TGF-β1) and α-smooth muscle actin (α-SMA) contributes to the progression of CKD to renal failure. In order to improve the solubility, bioavailability, and targeting of tanshinone IIA (Tan IIA), a novel targeting material, aminoethyl anisamide-polyethylene glycol-1,2-distearoyl-sn-glycero-3-phosphate ethanolamine (AEAA-PEG-DSPE, APD) modified Tan IIA liposomes (APD-Tan IIA-L) was constructed. An animal model of glomerulonephritis induced by doxorubicin in BALB/c mice was established. APD-Tan IIA-L significantly decreased blood urea nitrogen and serum creatinine (SCr), and the consequences of renal tissue oxidative stress indicators showed that APD-Tan IIA-L downregulated malondialdehyde, upregulated superoxide dismutase, catalase, and glutathione peroxidase. Masson's trichrome staining showed that the deposition of collagen in the APD-Tan IIA-L group decreased significantly. The pro-fibrotic factors (fibronectin, collagen I, TGF-β1, and α-SMA) and epithelial-mesenchymal transition marker (N-cadherin) were significantly inhibited by APD-Tan IIA-L. By improving the microenvironment of fibrotic kidneys, APD-Tan IIA-L attenuated TGF-β1-induced excessive proliferation of fibroblasts and alleviated oxidative stress damage to the kidney, providing a new strategy for the clinical treatment of renal fibrosis.
Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
PURPOSE: A composition for preventing acetaldehyde induced diseases, hangover prevention, and hangover curing is provided to rapidly metabolize acetaldehyde which is cause for various diseases and hangover. CONSTITUTION: A composition for preventing acetaldehyde induced diseases, hangover prevention, and hangover curing includes acetaldehyde dehydratase activator, mitochondria activator, anti-oxidant and cell death inhibitor. The acetaldehyde dehydratase activator is salt of calcium ion, magnesium ion, glutamate, L-cysteine or the salt thereof. The mitochondria activator is succinic acid, and glutamate or the salt thereof. The anti-oxidant is silymarin (in other words, milk thistle extract), catechin (in other words, green tea extract), vitamin C, thiamin, B2, B3, B4, B5, B6, B7, B8, B9 or B12. The cell death inhibitor is magnesium ion and creatine or the salt thereof. The composition includes silymarin (in other words, the milk thistle extract) or catechin (in other words, green tea extract) as an anti-oxidant.
The present invention is directed to a method and system for generating cost accounting data. The method may include retrieving information including descriptive attributes that represent content captured during patient care. The method may additionally include associating each descriptive attribute with a cost. A system may be provided for generating cost accounting information in a healthcare environment. The system may include automated information capture equipment and a retrieval component for retrieving content captured by the automated information capture equipment. The system may additionally include an association component for associating captured content with a cost and an implementation component for generating cost accounting information based on created associations.
In brief, at V1 subjects will be assessed for baseline spirometry and venous blood analysis prior to exposure. The venous blood will be used to obtain PMNs for apoptosis assays, and serum for CFH and sCD163 levels. Additionally, this will be used to measure cytokines and growth factors. At each visit, if the subject is female, there will be a urine pregnancy test performed. Following this initial assessment, subjects will be challenged with FA or O3 and then spirometry will be performed, and venous blood will be obtained immediately following the exposure (V2). The subjects will then return 20 hours ±4h later for follow up studies (V3). There will be spirometry, a venous blood draw and urine pregnancy testing (if female) followed by bronchoscopy. At bronchoscopy, vital signs will be determined, including O2 sat. Patient then undergo an 18-20 day washout period before they are brought back in for V4 for the alternate challenge. This will follow the same protocol as outline above in the initial exposure and use the same series of analysis as the first set of visits. Therefore, we will fully characterize the biological response to ozone and filtered air in these same subjects.
Massive bleeding resulting from civil and martial accidents can often lead to shock or even death, highlighting the critical need for the development of rapid and efficient hemostatic materials. While various types of hemostatic materials are currently utilized in clinical practice, they often come with limitations such as poor biocompatibility, toxicity, and biodegradability. Polysaccharides, such as alginate (AG), chitosan (CS), cellulose, starch, hyaluronic acid (HA), and dextran, have exhibit excellent biocompatibility and in vivo biodegradability. Their degradation products are non-toxic to surrounding tissues and can be absorbed by the body. As a result, polysaccharides have been extensively utilized in the development of hemostatic materials and have gained significant attention in the field of in vivo hemostasis. This review offers an overview of the different forms, hemostatic mechanisms, and specific applications of polysaccharides. Additionally, it discusses the future opportunities and challenges associated with polysaccharide-based hemostats.
Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.
In this study, we will explore mechanisms of exacerbation in asthma by careful characterization studies in asthmatics presenting in acute severe exacerbation. Specifically, we will determine the frequency of secretor status in these subjects by blood and saliva testing, and we will also perform a detailed cellular and biochemical analysis of their airway secretions. We will collect airway secretions using two methods. One method will be to have subjects cough sputum into a clean plastic container. The other method only applies to asthmatics with near-fatal asthma requiring intubation and mechanical ventilation. In these asthmatics, we will collect airway secretions by tracheal aspirate using methods normally applied in their clinical care.